# A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

> **NCT00094926** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 275 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Risperdal Consta
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00094926
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2011-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094926, "A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00094926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*